ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder - StreetInsider.com
Submitted by Anonymous (not verified) on Tue, 07/05/2022 - 05:00
